{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:41:57Z","timestamp":1787020917484,"version":"build-2736575974"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":42,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["1R01AG058660"],"award-info":[{"award-number":["1R01AG058660"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["1R01AG058660"],"award-info":[{"award-number":["1R01AG058660"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["1R01AG058660"],"award-info":[{"award-number":["1R01AG058660"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["1R01AG058660"],"award-info":[{"award-number":["1R01AG058660"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["1R01AG058660"],"award-info":[{"award-number":["1R01AG058660"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["1R01AG058660"],"award-info":[{"award-number":["1R01AG058660"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002565","name":"Alzheimer's Drug Discovery Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Zervimesine (CT1812) is an investigational brain-penetrant small molecule modulator of the sigma-2 receptor (S2R\/\n                      <jats:italic>TMEM97<\/jats:italic>\n                      ), currently in clinical development for the treatment of Alzheimer\u2019s disease (AD) and dementia with Lewy bodies (DLB) that selectively prevents and displaces the binding of amyloid beta (A\u03b2) and \u03b1-synuclein oligomers from neuronal synapses. Given the mechanism of action, it was hypothesized that zervimesine might be more effective in patients with lower levels of AD pathology. Indeed, in the SHINE trial, a completed Phase 2, randomized, double-blind, clinical trial conducted in participants with AD, a robust, 95%, slowing of cognitive decline, as assessed via ADAS-Cog11, was observed in a pre-specified subgroup of participants with lesser AD pathology (i.e., low p-tau217 subgroup) compared to a 38% slowing in the overall modified intent-to-treat (mITT)) population.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In SHINE, exploratory plasma biomarkers were assessed using both a targeted and an unbiased, proteomics discovery approach in plasma from participants at baseline and end of study. Treatment effects of zervimesine relative to placebo were assessed in both the mITT population and in a low p-tau217 subgroup, who entered the study with lower (&lt;\u20091pg\/ml) plasma p-tau217 concentrations. Plasma biomarkers A\u03b240, A\u03b242, GFAP, NfL and BD-tau were assessed using clinically validated targeted assays, along with untargeted TMT-mass spectrometry (MS)-based discovery proteomics followed by bioinformatic, pathway and correlation analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Collectively, plasma biomarker findings in the low p-tau217 subgroup were more robust than in the mITT population. Levels of GFAP were significantly decreased and NfL, A\u03b242 and A\u03b240 levels trended towards a decrease with zervimesine compared to placebo. Proteomics analyses identified candidate pharmacodynamic biomarkers of zervimesine, and gene ontology and pathway analyses pointed to an impact on amyloid biology, trafficking, lipid metabolism, and immune response. Bioinformatics and correlation analyses with GFAP identified biomarkers that may reflect pathway engagement of S2R and\/or decreased neuroinflammation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Exploratory plasma biomarker findings align with the degree of clinical benefit in SHINE mITT and low p-tau217 populations, and support future trial enrichment with patients with lower levels of pathology as defined by lower baseline plasma levels of p-tau217.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      July 20th, 2018 ClinicalTrials.gov Identifier NCT03507790\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT03507790\" ext-link-type=\"uri\">https:\/\/clinicaltrials.gov\/study\/NCT03507790<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-026-02025-4","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T05:55:24Z","timestamp":1775454924000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of zervimesine on the neuroinflammatory biomarker GFAP and related proteomic molecular correlates in plasma of participants from a phase 2 clinical trial in Alzheimer\u2019s disease"],"prefix":"10.1186","volume":"18","author":[{"given":"Valentina","family":"Di Caro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunah","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Thiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britney N.","family":"Lizama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marleen J.A.","family":"Koel-Simmelink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duc","family":"Duong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas T.","family":"Seyfried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Grundman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte E.","family":"Teunissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony O.","family":"Caggiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary E.","family":"Hamby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,6]]},"reference":[{"key":"2025_CR1","doi-asserted-by":"publisher","unstructured":"Izzo NJ, Yuede CM, LaBarbera KM, Limegrover CS, Rehak C, Yurko R, et al. Preclinical and clinical biomarker studies of CT1812: a novel approach to Alzheimer\u2019s disease modification. Alzheimers Dement. 2021;17:1365\u201382. https:\/\/doi.org\/10.1002\/alz.12302.","DOI":"10.1002\/alz.12302"},{"key":"2025_CR2","doi-asserted-by":"publisher","unstructured":"LaBarbera KM, Sheline YI, Izzo NJ, Yuede CM, Waybright L, Yurko R, et al. A phase 1b randomized clinical trial of CT1812 to measure A\u03b2 oligomer displacement in Alzheimer\u2019s disease using an indwelling CSF catheter. Transl Neurodegener. 2023;12:10\u20133. https:\/\/doi.org\/10.1186\/s40035-023-00358-w.","DOI":"10.1186\/s40035-023-00358-w"},{"key":"2025_CR3","unstructured":"Cognition Therapeutics. Effect of CT1812 Treatment on Brain Synaptic Density ClinicalTrials.gov identifier: NCT03493282. 2023 [cited 2026 Feb 8]. https:\/\/clinicaltrials.gov\/study\/NCT03493282?term=NCT03493282&rank=1. Accessed 8 Feb 2026"},{"key":"2025_CR4","doi-asserted-by":"publisher","unstructured":"van Dyck CH, Mecca AP, O\u2019Dell RS, Bartlett HH, Diepenbrock NG, Huang Y, et al. A pilot study to evaluate the effect of CT1812 treatment on synaptic density and other biomarkers in Alzheimer\u2019s disease. Alzheimers Res Ther. 2024;16:20. https:\/\/doi.org\/10.1186\/s13195-024-01382-2.","DOI":"10.1186\/s13195-024-01382-2"},{"key":"2025_CR5","doi-asserted-by":"publisher","first-page":"6860","DOI":"10.1002\/alz.14152","volume":"20","author":"BN Lizama","year":"2024","unstructured":"Lizama BN, Williams C, North HA, Pandey K, Duong D, Di Caro V, et al. CT1812 biomarker signature from a meta-analysis of CSF proteomic findings from two Phase 2 clinical trials in Alzheimer\u2019s disease. Alzheimers Dement. 2024;20:6860\u201380. https:\/\/doi.org\/10.1002\/alz.14152.","journal-title":"Alzheimers Dement"},{"key":"2025_CR6","doi-asserted-by":"publisher","unstructured":"Lizama BN, North HA, Pandey K, Williams C, Duong D, Cho E, et al. An interim exploratory proteomics biomarker analysis of a phase 2 clinical trial to assess the impact of CT1812 in Alzheimer\u2019s disease. Neurobiol Dis. 2024;199:106575. https:\/\/doi.org\/10.1016\/j.nbd.2024.106575.","DOI":"10.1016\/j.nbd.2024.106575"},{"key":"2025_CR7","unstructured":"Cognition Therapeutics. A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer\u2019s Disease. ClinicalTrials.gov identifier: NCT035077. 2025 [cited 2026 Feb 4]. Accessed 4 Feb 2026. https:\/\/clinicaltrials.gov\/study\/NCT03507790."},{"key":"2025_CR8","doi-asserted-by":"publisher","unstructured":"Vijverberg EGB, Scharre DW, Woodward M, Catalano S, Hamby ME, Grundman M, et al. Randomized, Double-Blind Study of Zervimesine in Mild to Moderate Alzheimer\u2019s Disease. Journal of Alzheimer's Disease. 2026. https:\/\/doi.org\/10.1177\/13872877261437145.","DOI":"10.1177\/13872877261437145"},{"key":"2025_CR9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1001\/jamaneurol.2023.4596","volume":"81","author":"N Mattsson-Carlgren","year":"2024","unstructured":"Mattsson-Carlgren N, Collij LE, Stomrud E, Pichet Binette A, Ossenkoppele R, Smith R, et al. Plasma biomarker strategy for selecting patients with Alzheimer disease for antiamyloid immunotherapies. JAMA Neurol. 2024;81:69\u201378. https:\/\/doi.org\/10.1001\/jamaneurol.2023.4596.","journal-title":"JAMA Neurol"},{"key":"2025_CR10","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","volume":"21","author":"CE Teunissen","year":"2022","unstructured":"Teunissen CE, Verberk IMW, Thijssen EH, Vermunt L, Hansson O, Zetterberg H, et al. Blood-based biomarkers for Alzheimer\u2019s disease: towards clinical implementation. Lancet Neurol. 2022;21:66\u201377. https:\/\/doi.org\/10.1016\/S1474-4422(21)00361-6.","journal-title":"Lancet Neurol"},{"key":"2025_CR11","doi-asserted-by":"publisher","unstructured":"Ashton NJ, Brum WS, Di Molfetta G, Benedet AL, Arslan B, Jonaitis E, et al. Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology. JAMA Neurol. 2024;81:255. https:\/\/doi.org\/10.1001\/jamaneurol.2023.5319.","DOI":"10.1001\/jamaneurol.2023.5319"},{"key":"2025_CR12","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/j.medj.2024.08.004","volume":"5","author":"Y Hu","year":"2024","unstructured":"Hu Y, Cho M, Sachdev P, Dage J, Hendrix S, Hansson O, et al. Fluid biomarkers in the context of amyloid-targeting disease-modifying treatments in Alzheimer\u2019s disease. Med. 2024;5:1206\u201326. https:\/\/doi.org\/10.1016\/j.medj.2024.08.004.","journal-title":"Med"},{"key":"2025_CR13","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202114022","volume":"13","author":"N Mattsson-Carlgren","year":"2021","unstructured":"Mattsson-Carlgren N, Janelidze S, Bateman RJ, Smith R, Stomrud E, Serrano GE, et al. Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau. EMBO Mol Med. 2021;13:e14022. https:\/\/doi.org\/10.15252\/emmm.202114022.","journal-title":"EMBO Mol Med"},{"key":"2025_CR14","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","volume":"81","author":"NJ Ashton","year":"2024","unstructured":"Ashton NJ, Brum WS, Molfetta GD, Benedet AL, Arslan B, Jonaitis E, et al. Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology. JAMA Neurol. 2024;81:255\u201363. https:\/\/doi.org\/10.1001\/jamaneurol.2023.5319.","journal-title":"JAMA Neurol"},{"key":"2025_CR15","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1056\/NEJMc2109455","volume":"385","author":"MA Mintun","year":"2021","unstructured":"Mintun MA, Wessels AM, Sims JR. Donanemab in early Alzheimer\u2019s disease. N Engl J Med. 2021;385:666\u20137. https:\/\/doi.org\/10.1056\/NEJMc2109455.","journal-title":"N Engl J Med"},{"key":"2025_CR16","doi-asserted-by":"publisher","unstructured":"Vasudeva R, Doty E, Yang F, Evans C, Zimmer J, Lu M, et al. The Importance of Early Recognition and Treatment Initiation for Managing Alzheimer\u2019s disease: Subpopulation Analysis of the TRAILBLAZER-ALZ 2 Randomized Trial (S23.005). Neurology. 2025;104. https:\/\/doi.org\/10.1212\/WNL.0000000000210512.","DOI":"10.1212\/WNL.0000000000210512"},{"key":"2025_CR17","unstructured":"Sperling RA, Selkoe DJ, Reyderman L, Cao Y, van Dyck CH. Does the Current Evidence Base Support Lecanemab Continued Dosing for Early Alzheimer\u2019s Disease? [Perspectives Session]. Alzheimer\u2019s Assoc Int Conf. Philadelphia, PA; 2024."},{"key":"2025_CR18","doi-asserted-by":"publisher","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023;330:512\u201327. https:\/\/doi.org\/10.1001\/jama.2023.13239.","DOI":"10.1001\/jama.2023.13239"},{"key":"2025_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1326-4-48","volume":"4","author":"GM Shankar","year":"2009","unstructured":"Shankar GM, Walsh DM. Alzheimer\u2019s disease: synaptic dysfunction and Abeta. Mol Neurodegener. 2009;4:48. https:\/\/doi.org\/10.1186\/1750-1326-4-48.","journal-title":"Mol Neurodegener"},{"key":"2025_CR20","unstructured":"Cognition Therapeutics. Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer\u2019s Disease Surpasses 50% Enrollment Target [Press Release]. 2025 Jul 1; https:\/\/ir.cogrx.com\/press_releases\/cognition-therapeutics-study-of-zervimesine-ct1812-in-early-alzheimers-disease-surpasses-50-enrollment-target\/."},{"key":"2025_CR21","unstructured":"Cognition Therapeutics. Cognition Therapeutics\u2019 Analysis Correlates Biomarker Changes with Cognitive Benefit in Alzheimer\u2019s Population [Press Release]. 2024 Nov 25; https:\/\/ir.cogrx.com\/press_releases\/cognition-therapeutics-analysis-correlates-biomarker-changes-with-cognitive-benefit-in-alzheimers-population\/."},{"key":"2025_CR22","unstructured":"Cognition Therapeutics. Cognition Therapeutics presents phase 3 plan for zervimesine (CT1812) in Alzheimer\u2019s disease at Clinical Trials on Alzheimer\u2019s Disease (CTAD) conference. [Press Release]. 2025 Dec 1; https:\/\/ir.cogrx.com\/press_releases\/cognition-therapeutics-presents-phase-3-plan-for-zervimesine-ct1812-in-alzheimers-disease-at-clinical-trials-on-alzheimers-disease-ctad-conference\/."},{"key":"2025_CR23","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1158\/1078-0432.CCR-17-1552","volume":"24","author":"S Matsui","year":"2018","unstructured":"Matsui S, Crowley J. Biomarker-stratified phase III clinical trials: enhancement with a subgroup-focused sequential design. Clin Cancer Res. 2018;24:994\u20131001. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-1552.","journal-title":"Clin Cancer Res"},{"key":"2025_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2023.121396","volume":"455","author":"F Gonzalez-Ortiz","year":"2023","unstructured":"Gonzalez-Ortiz F, Karikari T, Zetterberg H, Blennow K. Brain-derived tau in blood as a biomarker for Alzheimer\u2019s disease-type neurodegeneration. J Neurol Sci. 2023;455:121396. https:\/\/doi.org\/10.1016\/j.jns.2023.121396.","journal-title":"J Neurol Sci"},{"key":"2025_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-024-00757-1","volume":"19","author":"Q Guo","year":"2024","unstructured":"Guo Q, Ping L, Dammer EB, Duong DM, Yin L, Xu K, et al. Heparin-enriched plasma proteome is significantly altered in Alzheimer\u2019s disease. Mol Neurodegener. 2024;19:67. https:\/\/doi.org\/10.1186\/s13024-024-00757-1.","journal-title":"Mol Neurodegener"},{"key":"2025_CR26","doi-asserted-by":"publisher","unstructured":"Di Caro V, Cho E, North HA, Caldwell J, Pandey K, Duong D, et al. Identification of cerebrospinal fluid pharmacodynamic biomarkers and molecular correlates of brain activity in a Phase 2 clinical trial of the Alzheimer\u2019s disease drug candidate CT1812. Alzheimer\u2019s Dement. 2025;11(2):e70119. https:\/\/doi.org\/10.1002\/trc2.70119.","DOI":"10.1002\/trc2.70119"},{"key":"2025_CR27","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1093\/brain\/awab223","volume":"144","author":"JB Pereira","year":"2021","unstructured":"Pereira JB, Janelidze S, Smith R, Mattsson-Carlgren N, Palmqvist S, Teunissen CE, et al. Plasma GFAP is an early marker of amyloid-\u03b2 but not tau pathology in Alzheimer\u2019s disease. Brain. 2021;144:3505\u201316. https:\/\/doi.org\/10.1093\/brain\/awab223.","journal-title":"Brain"},{"key":"2025_CR28","doi-asserted-by":"publisher","unstructured":"Phillips JM, Winfree RL, Seto M, Schneider JA, Bennett DA, Dumitrescu LC, et al. Pathologic and clinical correlates of region-specific brain GFAP in Alzheimer\u2019s disease. Acta Neuropathol. Springer Science and Business Media Deutschland GmbH; 2024;148. https:\/\/doi.org\/10.1007\/s00401-024-02828-5.","DOI":"10.1007\/s00401-024-02828-5"},{"key":"2025_CR29","doi-asserted-by":"publisher","unstructured":"Cicognola C, Janelidze S, Hertze J, Zetterberg H, Blennow K, Mattsson-Carlgren N, et al. Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment. Alzheimers Res Ther. 2021;13:68. https:\/\/doi.org\/10.1186\/s13195-021-00804-9.","DOI":"10.1186\/s13195-021-00804-9"},{"key":"2025_CR30","unstructured":"Lilly. Results from Lilly\u2019s Landmark Phase 3 Trial of Donanemab Presented at Alzheimer\u2019s Association Conference and Published in JAMA [Press Release]. 2023 Jul 17; https:\/\/investor.lilly.com\/news-releases\/news-release-details\/results-lillys-landmark-phase-3-trial-donanemab-presented."},{"key":"2025_CR31","unstructured":"Eisai. New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI\u00ae (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer\u2019s Disease Patients Presented at AAIC 2024. [Press Release]. 2024. https:\/\/www.eisai.com\/news\/2024\/news202456.html."},{"key":"2025_CR32","doi-asserted-by":"publisher","unstructured":"Devanarayan V, Charil A, Horie K, Doherty T, Llano DA, Andreozzi E, et al. Plasma pTau217 ratio predicts continuous regional brain tau accumulation in amyloid-positive early Alzheimer\u2019s disease. Alzheimers Dement. 2025;21:e14411. https:\/\/doi.org\/10.1002\/alz.14411.","DOI":"10.1002\/alz.14411"},{"issue":"12","key":"2025_CR33","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1001\/jamaneurol.2021.3671","volume":"78","author":"AL Benedet","year":"2021","unstructured":"Benedet AL, Mil\u00e0-Alom\u00e0 M, Vrillon A, Ashton NJ, Pascoal TA, Lussier F, et al. Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum. JAMA Neurol. 2021;78:1471. https:\/\/doi.org\/10.1001\/jamaneurol.2021.3671.","journal-title":"JAMA Neurol"},{"key":"2025_CR34","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s43587-023-00403-3","volume":"3","author":"O Hansson","year":"2023","unstructured":"Hansson O, Blennow K, Zetterberg H, Dage J. Blood biomarkers for Alzheimer\u2019s disease in clinical practice and trials. Nat Aging. 2023;3:506\u201319. https:\/\/doi.org\/10.1038\/s43587-023-00403-3.","journal-title":"Nat Aging"},{"key":"2025_CR35","doi-asserted-by":"publisher","first-page":"813","DOI":"10.3233\/JAD-160722","volume":"55","author":"P Lewczuk","year":"2016","unstructured":"Lewczuk P, Matzen A, Blennow K, Parnetti L, Molinuevo JL, Eusebi P, et al. Cerebrospinal fluid A\u03b242\/40 corresponds better than A\u03b242 to amyloid PET in Alzheimer\u2019s disease. J Alzheimers Dis. 2016;55:813\u201322. https:\/\/doi.org\/10.3233\/JAD-160722.","journal-title":"J Alzheimers Dis"},{"key":"2025_CR36","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-023-02679-6","volume":"147","author":"M Colom-Cadena","year":"2024","unstructured":"Colom-Cadena M, Toombs J, Simzer E, Holt K, McGeachan R, Tulloch J, et al. Transmembrane protein 97 is a potential synaptic amyloid beta receptor in human Alzheimer\u2019s disease. Acta Neuropathol. 2024;147:32. https:\/\/doi.org\/10.1007\/s00401-023-02679-6.","journal-title":"Acta Neuropathol"},{"key":"2025_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21197058","volume":"21","author":"H Miranzadeh Mahabadi","year":"2020","unstructured":"Miranzadeh Mahabadi H, Taghibiglou C. Cellular prion protein (PrPc): putative interacting partners and consequences of the interaction. Int J Mol Sci. 2020;21:7058. https:\/\/doi.org\/10.3390\/ijms21197058.","journal-title":"Int J Mol Sci"},{"key":"2025_CR38","doi-asserted-by":"publisher","first-page":"28625","DOI":"10.1073\/pnas.2009238117","volume":"117","author":"AR Foley","year":"2020","unstructured":"Foley AR, Roseman GP, Chan K, Smart A, Finn TS, Yang K, et al. Evidence for aggregation-independent, PrP C -mediated A\u03b2 cellular internalization. Proc Natl Acad Sci. 2020;117:28625\u201331. https:\/\/doi.org\/10.1073\/pnas.2009238117.","journal-title":"Proc Natl Acad Sci"},{"key":"2025_CR39","doi-asserted-by":"publisher","unstructured":"Izzo NJ, Staniszewski A, To L, Fa M, Teich AF, Saeed F, et al. Alzheimer\u2019s therapeutics targeting amyloid beta 1\u201342 oligomers I: abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits. PLoS One. 2014;9:e111898. https:\/\/doi.org\/10.1371\/journal.pone.0111898.","DOI":"10.1371\/journal.pone.0111898"},{"key":"2025_CR40","doi-asserted-by":"publisher","unstructured":"Izzo NJ, Xu J, Zeng C, Kirk MJ, Mozzoni K, Silky C, et al. Alzheimer\u2019s therapeutics targeting amyloid beta 1\u201342 oligomers II: sigma-2\/PGRMC1 receptors mediate abeta 42 oligomer binding and synaptotoxicity. PLoS One. 2014;9:e111899. https:\/\/doi.org\/10.1371\/journal.pone.0111899.","DOI":"10.1371\/journal.pone.0111899"},{"key":"2025_CR41","doi-asserted-by":"publisher","unstructured":"LizamaBN, Kahle J, Catalano SM, Caggiano AO, Grundman M, Hamby ME. Sigma-2 Receptors\u2014From Basic Biology to Therapeutic Target: A Focus on Age-Related Degenerative Diseases. Int. J. Mol. Sci. 2023;24(7):6251. https:\/\/doi.org\/10.3390\/ijms24076251.","DOI":"10.3390\/ijms24076251"},{"key":"2025_CR42","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.255752","author":"T Burrinha","year":"2021","unstructured":"Burrinha T, Martinsson I, Gomes R, Terrasso AP, Gouras GK, Almeida CG. Upregulation of APP endocytosis by neuronal aging drives amyloid-dependent synapse loss. J Cell Sci. 2021. https:\/\/doi.org\/10.1242\/jcs.255752.","journal-title":"J Cell Sci"},{"key":"2025_CR43","doi-asserted-by":"publisher","unstructured":"Xicota L, Lagarde J, Eysert F, Grenier-Boley B, Rivals I, Bott\u00e9 A, et al. Modifications of the endosomal compartment in fibroblasts from sporadic Alzheimer\u2019s disease patients are associated with cognitive impairment. Transl Psychiatry. 2023. https:\/\/doi.org\/10.1038\/s41398-023-02355-z.","DOI":"10.1038\/s41398-023-02355-z"},{"key":"2025_CR44","doi-asserted-by":"publisher","unstructured":"Rhinn H, Tatton N, McCaughey S, Kurnellas M, Rosenthal A, Elsevier Ltd. Progranulin as a therapeutic target in neurodegenerative diseases. Trends Pharmacol Sci. 2022. https:\/\/doi.org\/10.1016\/j.tips.2021.11.015.","DOI":"10.1016\/j.tips.2021.11.015"},{"key":"2025_CR45","doi-asserted-by":"publisher","unstructured":"Brosig A, Fuchs J, Ipek F, Kroon C, Schr\u00f6tter S, Vadhvani M, et al. The axonal membrane protein PRG2 inhibits PTEN and directs growth to branches. Cell Rep. 2019;29:2028-2040.e8. https:\/\/doi.org\/10.1016\/j.celrep.2019.10.039.","DOI":"10.1016\/j.celrep.2019.10.039"},{"key":"2025_CR46","doi-asserted-by":"publisher","unstructured":"Riad A, Zeng C, Weng C-C, Winters H, Xu K, Makvandi M, et al. Sigma-2 receptor\/TMEM97 and PGRMC-1 increase the rate of internalization of LDL by LDL receptor through the formation of a ternary complex. Sci Rep. 2018;8:16845. https:\/\/doi.org\/10.1038\/s41598-018-35430-3.","DOI":"10.1038\/s41598-018-35430-3"},{"key":"2025_CR47","doi-asserted-by":"publisher","unstructured":"Althaher AR, S. AL Shehadeh R. Lipoprotein Lipase and Neurological Health: Investigating its Impact on Brain Function and Alzheimer\u2019s Disease. Open Biomark J. 2024;14. https:\/\/doi.org\/10.2174\/0118753183367402241216115139.","DOI":"10.2174\/0118753183367402241216115139"},{"key":"2025_CR48","doi-asserted-by":"publisher","unstructured":"Reimand J, Isserlin R, Voisin V, Kucera M, Tannus-Lopes C, Rostamianfar A, et al. Pathway enrichment analysis and visualization of omics data using g:Profiler, GSEA, Cytoscape and EnrichmentMap. Nat Protoc. 2019;14:482\u2013517. https:\/\/doi.org\/10.1038\/s41596-018-0103-9.","DOI":"10.1038\/s41596-018-0103-9"},{"key":"2025_CR49","doi-asserted-by":"publisher","unstructured":"Panyard DJ, Reus LM, Ali M, Liu J, Deming YK, Lu Q, et al. Post-GWAS multiomic functional investigation of the TNIP1 locus in Alzheimer\u2019s disease highlights a potential role for GPX3. Alzheimers Dement. 2024;20:5044\u201353. https:\/\/doi.org\/10.1002\/alz.13848.","DOI":"10.1002\/alz.13848"},{"key":"2025_CR50","doi-asserted-by":"publisher","unstructured":"Savage MJ, Iqbal M, Loh T, Trusko SP, Scott R, Siman R. Cathepsin G: localization in human cerebral cortex and generation of amyloidogenic fragments from the \u03b2-amyloid precursor protein. Neuroscience. 1994;60:607\u201319. https:\/\/doi.org\/10.1016\/0306-4522(94)90490-1.","DOI":"10.1016\/0306-4522(94)90490-1"},{"key":"2025_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.tins.2023.03.007","author":"CM Alberini","year":"2023","unstructured":"Alberini CM. IGF2 in memory, neurodevelopmental disorders, and neurodegenerative diseases. Trends Neurosci. 2023. https:\/\/doi.org\/10.1016\/j.tins.2023.03.007.","journal-title":"Trends Neurosci"},{"key":"2025_CR52","doi-asserted-by":"publisher","unstructured":"Yu XW, Pandey K, Katzman AC, Alberini CM. A role for CIM6P\/IGF2 receptor in memory consolidation and enhancement. Elife. 2020;9:1\u201325. https:\/\/doi.org\/10.7554\/eLife.54781.","DOI":"10.7554\/eLife.54781"},{"key":"2025_CR53","doi-asserted-by":"publisher","unstructured":"Vagnoni A, Perkinton MS, Gray EH, Francis PT, Noble W, Miller CCJ. Calsyntenin-1 mediates axonal transport of the amyloid precursor protein and regulates a\u03b2 production. Hum Mol Genet. 2012;21:2845\u201354. https:\/\/doi.org\/10.1093\/hmg\/dds109.","DOI":"10.1093\/hmg\/dds109"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-026-02025-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-026-02025-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-026-02025-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:30:51Z","timestamp":1781645451000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13195-026-02025-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,6]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2025"],"URL":"https:\/\/doi.org\/10.1186\/s13195-026-02025-4","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,6]]},"assertion":[{"value":"15 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the International Conference on Harmonization Tripartite Guideline for Good Clinical Practice, and the Guidelines of the Declaration of Helsinki. The study protocol and informed consent form were reviewed and approved by an institutional review board. All participants and their caregivers provided written informed consent prior to any study procedures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"VD, EC, JT, BNL, AOC, and MEH are or were former employees and are shareholders of Cognition Therapeutics, Inc. MG is a consultant to and shareholder in Cognition Therapeutics. DD, NTS, and KP are co-founders, employees, consultants, and\/or shareholders of EmTheraPro. CET has research contracts with Acumen, ADx Neurosciences, AC-Immune, Alamar, Aribio, Axon Neurosciences, Beckman-Coulter, BioConnect, Bioorchestra, Brainstorm Therapeutics, Celgene, Cognition Therapeutics, EIP Pharma, Eisai, Eli Lilly, Fujirebio, Instant Nano Biosensors, Novo Nordisk, Olink, PeopleBio, Quanterix, Roche, Toyama, Vivoryon. She is editor in chief of Alzheimer Research and Therapy, and serves on editorial boards of Molecular Neurodegeneration, Neurology: Neuroimmunology & Neuroinflammation, Medidact Neurologie\/Springer, and serves on committee to define guidelines for Cognitive disturbances, and one for acute Neurology in the Netherlands. She had consultancy\/speaker contracts for Aribio, Biogen, Beckman-Coulter, Cognition Therapeutics, Eli Lilly, Merck, Novo Nordisk, Olink, Roche and Veravas. HZ has served at scientific advisory boards and\/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZpath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Enigma, LabCorp, Merck Sharp & Dohme, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Quanterix, Red Abbey Labs, reMYND, Roche, Samumed, ScandiBio Therapeutics AB, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures sponsored by Alzecure, BioArctic, Biogen, Cellectricon, Fujirebio, LabCorp, Lilly, Novo Nordisk, Oy Medix Biochemica AB, Roche, and WebMD, is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, and is a shareholder of MicThera (outside submitted work). KB has served as a consultant and at advisory boards for Abbvie, AC Immune, ALZPath, AriBio, Beckman-Coulter, BioArctic, Biogen, Cognition Therapeutics, Eisai, Lilly, Moleac Pte. Ltd, Neurimmune, Novartis, Ono Pharma, Prothena, Quanterix, Roche Diagnostics, Sunbird Bio, Sanofi and Siemens Healthineers; has served at data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai and Roche Diagnostics; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, (outside submitted work).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"112"}}